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Objective:  To  evaluate  the  effectiveness  of a web based  decision  aid versus  a leaﬂet  versus,  usual  practice
in reducing  parents’  decisional  conﬂict  for the  ﬁrst  dose  MMR  vaccination  decision.  The,  impact  on  MMR
vaccine  uptake  was also  explored.
Design:  Three-arm  cluster  randomised  controlled  trial.  Setting:  Fifty  GP  practices  in the  north  of,  England.
Participants:  220  ﬁrst  time  parents  making  a ﬁrst  dose  MMR  decision.  Interventions:  Web,  based  MMR
decision  aid  plus  usual  practice,  MMR  leaﬂet  plus  usual  practice  versus  usual  practice  only,  (control).  Main
outcome  measures:  Decisional  conﬂict  was  the  primary  outcome  and  used  as  the,  measure  of  parents’
levels  of informed  decision-making.  MMR  uptake  was  a  secondary  outcome.
Results: Decisional  conﬂict  decreased  post-intervention  for both  intervention  arms  to  a level  where,  par-
ents could  make  an  informed  MMR  decision  (decision  aid:  effect  estimate  = 1.09,  95%  CI  −1.36 to −0.82;
information  leaﬂet:  effect  estimate  = −0.67,  95%  CI  −0.88  to −0.46).  Trial  arm  was  signiﬁcantly,  asso-
ciated  (p  < 0.001)  with  decisional  conﬂict  at post-intervention.  Vaccination  uptake  was  100%,  91%,  and
99%  in  the  decision  aid,  leaﬂet  and  control  arms,  respectively  (2 (1, N =  203) = 8.69;  p  =  0.017).  Post-hoc
tests  revealed  a statistically  signiﬁcant  difference  in  uptake  between  the information  leaﬂet,  and  the
usual  practice  arms  (p  =  0.04),  and  a near  statistically  signiﬁcant  difference  between  the, decision  aid  and
leaﬂet arms  (p = 0.05).
Conclusions:  Parents’  decisional  conﬂict  was  reduced  in  both,  the  decision  aid and  leaﬂet  arms.  The  deci-
sion  aid  also  prompted  parents  to act  upon  that  decision  and,  vaccinate  their  child.  Achieving  both
outcomes  is  fundamental  to  the  integration  of  immunisation,  decision  aids  within  routine  practice.  Trial
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1. Introduction
In England and Wales, the decline in MMR  uptake follow-
ing Wakeﬁeld’s now discredited study [1] continues to reverse
[2]. However uptake remains below the 95% target required for
population immunity at 92% (1st dose by 24 months) and 88%
(1st and 2nd dose by 5 years) [3]. The incidence of measles
is at its highest for 18 years [4]. More widely, over 20 000
cases of measles were reported in 51 countries within the
WHO European Region from January to October 2012 [5]. In the
Open access under CC BY-NC-SA license.USA, where childhood immunisation is mandatory, 211 cases
of measles were conﬁrmed in 2011 the highest levels since
1996 [6]. These outbreaks are partially attributable to vaccine
refusal [6,7] and strategies targeting different groups of parents
SA license. 
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ho do not vaccinate their children continue to be needed
8,9].
Typically Government information about MMR  vaccination, for
xample ‘MMR  the facts’ [10], emphasises the risks of not having
he vaccine with the aim of increasing uptake. Patient decision aids
re a different type of information resource that provide detailed
nformation on the probable risks and beneﬁts of having and not
aving the MMR  vaccination. Decision aids also encourage people
o actively evaluate this information in accordance with their val-
es, to make a decision [11]. Encouraging people to deliberate about
heir MMR  beliefs may  affect their motivation to vaccinate [12–14]
ence their underuse in this context.
Few studies have evaluated decision aids for childhood immun-
sation decisions. In New Zealand, a childhood immunisation paper
ased decision aid reduced parent’s anxiety about making the deci-
ion and encouraged promptness in vaccination [15]. An Australian
MR vaccination web based decision aid resulted in parents hav-
ng more positive views towards MMR,  feeling more informed and
eaning towards vaccination [16]. This decision aid was subse-
uently adapted for UK parents and its feasibility evaluated [17].
he ﬁndings suggested that the decision aid may  support both
nformed decision-making and vaccination uptake. Finally an MMR
eaﬂet [18] was compared with the leaﬂet plus a community-based
ecision support intervention [19]. Parents in both groups felt more
ble to make an informed decision with those receiving the com-
unity intervention signiﬁcantly more likely to take their child to
e vaccinated. These studies suggest that interventions focusing
n the decision-making process for MMR  vaccination are associ-
ted with parents making informed decisions, and may  also impact
ositively on vaccine uptake. However, with the exception of Jack-
on et al. [19], evaluations have used quasi-experimental designs
nd so cannot provide conclusive evidence of effectiveness.
This paper presents the ﬁndings from the ﬁrst cluster ran-
omised controlled trial to evaluate the effectiveness of a decision
id versus a leaﬂet versus usual practice for a childhood immunisa-
ion decision. Our primary interest was whether the decision aid
ompared with a leaﬂet could support parents’ informed decision-
aking about the MMR  vaccine. We  were also interested in their
mpact on MMR  uptake.
. Materials and methods
This was a three-arm cluster randomised controlled trial: MMR
ecision aid plus usual practice, MMR  leaﬂet plus usual practice
nd usual practice only (control). The study was approved by the
ork Ethics Committee (08/H1311/23), and registered on or about
1 October 2007 with the UK Clinical Research Network (UKCRN ID
811) [20].
.1. Participants and procedure
The UK childhood vaccination programme is administered pri-
arily through primary care via General Practices (GPs). All 312
P Practices within ﬁve Primary Care Providers (called Primary
are Trusts, PCTs) in the north of England were eligible to take part
nd offered £250 to participate. Uptake of ﬁrst dose MMR  ranged
rom 87% to 92% across the ﬁve PCTs at the time of the study [21].
irst-time parents with a child aged 3–12 months being offered the
rst dose of the MMR  vaccine were eligible. Parents were required
o have an email address and sufﬁcient English language skills to
articipate. On study completion, parents were offered a £10 gift
oucher.
Eligible parents identiﬁed through GP practice registers were
ent a postal invitation via their GP practice. Interested parents
eplied directly to the research team. Parents were then contacted1 (2013) 6003– 6010
by telephone (by SS, CJ) to conﬁrm eligibility, enrol in the study
and provide demographic data. The baseline questionnaire and
consent form were subsequently sent to the parent. After all the
baseline questionnaires had been sent out within a GP practice,
that practice was  randomised. On receipt of the completed base-
line questionnaire and consent form, the appropriate intervention
was delivered. At this point the researchers (SS, CJ) and partici-
pants were no longer blind to allocation. Only the statistician (WH)
remained blind. The follow-up questionnaire was sent two  weeks
later. First dose MMR  uptake data were collected from GP prac-
tices when children reached 15 months of age. Recruitment and
follow-up occurred May  2009 to end September 2010.
2.2. Randomisation
Simple randomisation using a computer-generated random list
allocated GP practices on a 1:1:1 basis. An independent researcher
who had no contact with participants generated the allocation
sequence and assigned the GP practices to their allocated arm.
2.3. Interventions
The interventions were delivered at the parent level.
2.3.1. MMR decision aid plus usual practice
Parents were posted the web link for the MMR  decision aid and
to reduce contamination risk were provided with a personal login
to access it. They continued to receive usual practice (described
below) from their GP practice. The decision aid was  a modiﬁed ver-
sion of the Australian MMR  decision aid [16]. It can be accessed at
www.leedsmmr.co.uk. Prior to this trial, it was assessed against
the International Patient Decision Aids Standards [IPDAS, 22]. A
description of the modiﬁed version, its adaptation and piloting is
published elsewhere [17]. An overview is presented in Fig. 1.
2.3.2. MMR leaﬂet plus usual practice
Parents were sent the Health Scotland leaﬂet ‘MMR your ques-
tions answered’ [18] and received usual practice. Our previous
research [19] found this leaﬂet to signiﬁcantly reduce parents’ deci-
sional conﬂict. An overview is presented in Fig. 1. The leaﬂet does
not meet IPDAS criteria [22] to be a decision aid.
2.3.3. Usual practice only (control)
Parents received the usual service provided by their GP practice.
Parents of children registered with a GP are invited to have their
child vaccinated for the ﬁrst dose MMR  at 12–13 months. Tele-
phone interviews with participating GP practices indicated that
usual practice typically included an appointment for the ﬁrst dose
MMR vaccination, a leaﬂet (usually ‘MMR  the Facts’ [10]), and the
offer of a consultation if the parent had concerns.
2.4. Measures
Demographic data were collected during the telephone contact
as described above: date of birth, ethnicity, highest educational
qualiﬁcation, employment status, household income, sex and date
of birth of the child.
Outcome data were collected at the individual parent level in
the baseline and 2-weeks post-intervention questionnaires. Previ-
ously, we  found two  weeks was  sufﬁcient time for parents to utilise
the resource they had been sent [19]. The baseline questionnaire is
provided as supplementary material.2.4.1. Primary outcome
Decisional conﬂict [23] assesses a parent’s perception that their
decision was  informed, in accordance with their values, and can
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 NOISICED TNETNOC
AID 
LEAFLET
Provisio n of infor mation 
What are the mumps, measles and rubella diseases  X - 
 X X eniccav RMM eht si tahW
How common the mumps, me asles and rubella diseases  are  in  the  UK  X - 
Rationale for including the MMR vaccine in  the Childhood 
Immuni sation  Schedule  
X - 
 - X skrow eniccav RMM eht woH
 - X sniatnoc eniccav RMM eht tahW
Age at  which the MMR vaccine is  given in  the Childhood  Im munisa tion 
Schedule
X  X 
Common  sy mptoms  of  measles, mumps and rubella diseases   X detailed   X brief 
Complications of  measles, mumps and rubella diseases  X detailed   X brief 
 feirb X deliated X eniccav RMM eht fo stceffe edis nommoC
 feirb X deliated X eniccav RMM eht fo snoitacilpmoc eraR
Comparison of  serious effects of  meas les, mumps and rubella  diseases 
and side effects of  MMR vaccine 
X  X 
Pictorial diagrams comparing the l ikeli hood  of the ri sks of  measles,  
mumps and rubella diseases and the MMR vaccine 
X - 
 X X eniccav RMM eht dna msitua neewteb ’knil‘ ehT
The ‘link’ between inflammatory bowel disease and the MMR vaccine   X X 
 X X seniccav elgnis gnisU
 X X eniccav RMM eht fo ytefaS
 X X  setisbew latnemnrevog KU ot sknil beW
 - X  setisbew latnemnrevog-non KU ot sknil beW
 - X  setisbew lanoitanretni detaler s ot sknil beW
References for the information provided in  the resource   X - 
Availa ble i n other langua ges  - X 
Prompting a decision-making process a
Parents prompted to  record their inte ntion a bout MMR  vacci nation  for 
their child (before they work through the decision aid) 
X - 
Information p rovi ded  on t he ad vantage s and di sadvan tage s of MM R 
vacci natio n
X - 
Parents prompted to  consider the reasons  FOR vaccinating  their  child   X - 
Parents prompted to  consider the reasons  for NOT vaccinating  their 
child
X - 
Parents prompted to  consider  their information needs  X - 
Parents prompted to  record their inte ntion a bout MMR  vacci nation  for 
their child (at the end of  working through the decision aid) 
X - 
aInteractive sections of  the MMR decision  aid 
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cFig. 1. Comparison of the content provid
e acted upon. This 16-item validated scale has ﬁve sub-sections:
nformed, values clarity, support, uncertainty and effective deci-
ion. Scores range from 1 (no decisional conﬂict) to 5 (extremely
igh decisional conﬂict). Scores lower than two are associated with
mplementing informed decisions, higher scores are interpreted as
elaying decisions or feeling unsure about their implementation
23].
.4.2. Secondary outcomes
First dose MMR  vaccination uptake data for children of participat-
ng parents were obtained from GP practice records (by practice
dministrators) when the child was aged 15 months.
Subscales of the decisional conﬂict scale: as presented above.
Knowledge about MMR  and the measles disease was  measured
sing 11 multiple choice items used in our previous research
17,19].MMR  immunisation cognitions:  The Theory of Planned Behaviour
24] informed items to assess parents’ cognitions (attitude, sub-
ective norm, perceived behavioural control) towards having their
hild immunised with MMR  at the recommended ages. the MMR  decision aid and MMR  leaﬂet.
MMR immunisation trade-off beliefs:  We  used a previously mod-
iﬁed version of the Beliefs about Flu Vaccination Questionnaire to
assess parents’ trade-off beliefs on vaccine necessity versus vac-
cine concerns for MMR  [25]. This measure has not been validated
for MMR  yet is associated with parents’ decisional conﬂict for MMR
[19]. We calculated a single MMR  immunisation ‘trade-off’ beliefs
score. A positive score indicates that the parent perceives that
necessity outweighs the concerns.
Anxiety was assessed by the short form State-Trait Anxiety
Index [26].
2.4.3. Parents’ engagement with the decision aid or leaﬂet
Data were collected in the post-intervention questionnaire. Par-
ents in the decision aid arm were asked ‘Did you use the MMR
website?’ (Yes the whole website/Yes but only some of it/No). The
time parents spent working through the decision aid was captured
by Google analytics. Parents in the leaﬂet arm were asked ‘Did you
read the MMR  leaﬂet?’ (Yes the whole leaﬂet/Yes but only some of
it/No). All parents were asked how long (minutes) they had spent
looking at other information about MMR  before or since their child
was born.
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Table 1
Baseline characteristics by arm.
No. (%)
Decision aid Leaﬂet Control
GP practices 14 (28) 18 (36) 18 (36)
Parents 50 (23) 93 (42) 77 (35)
Relationship to child
Mother 46 (92) 87 (94) 73 (95)
Father 4 (8) 6 (6) 4 (5)
Ethnicity
White British 49 (98) 82 (88) 70 (91)
Other 1 (2) 9 (10) 7 (9)
Missing 0 (0) 2 (2) 0 (0)
Marital status
Single/never married 2 (4) 4 (4) 4 (5)
Married/live with partner 47 (94) 86 (93) 73 (95)
Separated/divorced/widowed 0 (0) 2 (2) 0 (0)
Missing 1 (2) 1 (1) 0 (0)
Education
Up  to 18 years 22 (44) 32 (34) 31 (40)
Beyond 18 years 28 (56) 60 (65) 46 (60)
Missing 0 (0) 1 (1) 0 (0)
Employment
Full time 27 (54) 44 (47) 36 (47)
Part time 17 (34) 29 (31) 29 (38)
Other 6 (12) 19 (20) 11 (14)
Missing 0 (0) 1 (2) 1 (1)006 S. Shourie et al. / Vac
.5. Sample size
Based on the primary outcome of decisional conﬂict [23], to
etect an effect size of 0.5 [17] with a minimum power of 0.80 for
 2-sided signiﬁcance level of 0.05 and independent sampling, the
arget sample size required was 402 parents (134 parents per arm)
rom 42 clusters to achieve 360 parents (120 per arm) completing
he study. This estimate took into account 10% attrition and clus-
ering effects within GP practices of a sample size inﬂation factor
f 1.9 using an ICC of 0.1 and an estimated 10 parents per cluster
19].
.6. Statistical analysis
.6.1. Baseline balance
Differences in participants’ demographic characteristics and
aseline decisional conﬂict score across the three trial arms were
ssessed using one-way ANOVA (age of parent, age of child, deci-
ional conﬂict) and chi squared analysis (relationship to child,
thnicity, marital status, education, employment).
.6.2. Primary outcome
Intervention effect was assessed at the parental level but within
P practice clusters. Analyses were performed on an intention to
reat basis. All reported p-values are two sided, with p < 0.05 con-
idered as signiﬁcant. Analyses were carried out using STATA 11.0.
A multilevel model with GP practice at the upper level was
onstructed but found to not signiﬁcantly improve the model
ICC = 1.74 × 10−19, p > 0.999). Decisional conﬂict was analysed
sing Analysis of Covariance, where decisional conﬂict post-
ntervention was regressed onto decisional conﬂict at baseline,
arental demographics, trial arm and secondary outcomes at
aseline (see Section 2.4). The model was simpliﬁed by remov-
ng non-signiﬁcant items until only statistically signiﬁcant items
emained. Individual items were re-entered one at a time to check
f they inﬂuenced the simpliﬁed model. If an inﬂuence was detected,
he item was included.
Due to missing values resulting from non-completion of ques-
ionnaire items, complete case analyses corresponded to only 55%
f the data (121/220 parents). We  assumed that data were missing
t random (MAR) [27]. For each missing value variable we  imputed
ata using multiple imputation from all variables that we  consid-
red could reasonably inﬂuence the missing values. Although we
annot be conclusive that MAR  is justiﬁed sufﬁcient predictors of
he missing values were included to make this assumption plausi-
le [28]. Five imputed datasets were generated. The complete case
odel agreed on the importance of all signiﬁcant variables in the
odel ﬁtted to the imputed datasets and results were found to be
imilar indicating that minimal bias would have been introduced
ue to missing values. The best ﬁt model was determined for the
mputed datasets and aggregated results from the ﬁve imputed
atasets are presented.
.6.3. Secondary outcomes
Fisher’s Exact test assessed the impact of the intervention on
MR  uptake. Analysis was performed on an intention to treat basis.
Descriptive statistics (means, 95% conﬁdence intervals) were
alculated for the subscales of the decisional conﬂict scale at both
ime points and compared across allocated arm using repeated
easures ANOVAs. Where statistically signiﬁcant effects were
dentiﬁed, post hoc tests were performed. As the focus of this paper
s the impact of the interventions on informed decision-making
nd vaccine uptake, changes in other secondary outcome measures
knowledge, MMR  immunisation cognitions, MMR  immunisation
rade-off beliefs and anxiety) are not reported.Mean age (SD) of parent, years 32.20 (5.51) 33.29 (5.58) 31.43 (5.25)
Mean age (SD) of child, months 9.00 (2.35) 8.04 (2.63) 8.33 (2.40)
Frequencies were calculated for parents’ self-reported use of the
decision aid and leaﬂet. The mean amount of time parents spent
working through the MMR  decision aid was reported by Google
analytics. One way  ANOVA compared how long parents had spent
looking at other information about MMR  across the three arms.
3. Results
Fifty eight (19%) of 312 GP practices agreed to participate, of
which 50 (16%) provided parents and were randomised. A total
of 1179 parents were sent an invitation letter. Of  these 250 (21%)
replied. Thirty did not meet the inclusion criteria. Of  the 220 eligible
parents recruited 196 (89%) completed the study. This was equiv-
alent to 54% of the original target sample completing the study.
However, the ICC (1.74 × 10−19) and the average cluster size (4
parents) were both lower than the estimates used in the sample
size calculation (0.1, 10 parents, respectively) thus providing an
adequate sample to draw meaningful conclusions [29]. Participant
ﬂow through the study is presented in Fig. 2.
3.1. Baseline characteristics
Baseline characteristics are presented in Table 1. There were no
statistically signiﬁcant differences in parental or child character-
istics across the three trial arms (all p > 0.1). Most parents were
white British mothers, in their early 30s, married or co-habiting.
Approximately half were educated beyond 18 years and in full-time
employment. These characteristics are consistent with parents who
ﬁnd it difﬁcult to make an MMR  decision [30,31]. Children were 8–9
months old at recruitment.
3.2. Impact of the decision aid and leaﬂet interventions on
informed decision-making (decisional conﬂict)
At baseline there was  a statistically signiﬁcant difference in
decisional conﬂict across the three arms F(2,192) = 3.42, p = 0.04).
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All oca ted to  DA 
N = 14 GP practices 
N=50 parents 
Median No. parents = 2.5 
(Range 1 to 15) 
GP practices/parents did not 
receive intervention 
(N=0)
F
O
L
L
O
W
U
P
Allocate d to Leaflet 
N = 18 GP practices 
N=93 parents 
Median No. parents = 5 
(Range 1 to 12) 
GP practices/parents did not 
receive intervention 
(N=0)
Allocated to Control 
N = 18  GP  practices 
N=77 parents 
Median No. parents = 2.5
(Range 1 to 12) 
GP practices/parents did not 
receive intervention 
(N=0) 
A
L
L
O
C
A
T
I
O
N
A
N
A
L
Y
S
I
S
Excluded (n=262 GP practices): 
Refused to  participate (n=254) 
Did not provide parents (n=8) 
Assessed for eligibility (n=312 GP  practices) 
Randomised (n = 50 GP practices) 
E
N
R
O
L
M
E
N
T
Lost to  follow up 
N = 5 GP  practices 
N=6 parents did not return 
both questio nnaires  
Median No. parents = 1 
(Range 1 to 2) 
Lost to  follow up 
N = 8 GP  practices 
N=10 parents did not  ret urn 
both questio nnaires  
Median No. parents = 1 
(Range 1 to 2) 
Lost to  follow up 
N = 6 GP  practices 
N=8 parents did not return 
both questio nnaires  
Median No. parents = 1
(Range 1 to 2) 
Analysed a
N = 14  GP  practices 
N=50 parents 
Median No. parents = 3 
(Range 1 to 15) 
GP practices/parents 
exclu ded fr om prima ry 
outcome analysis (N=0)
Analysed a
N = 18  GP  practices 
N=93 parents 
Median No. parents = 4 
(Range 1 to 12) 
GP practices/parents 
excluded fr om prima ry 
outcome analysis (N=0)
Analysed a
N = 18  GP  practices 
N=77 parents 
Median No. parents = 4 
(Range 1 to 12) 
GP practices/parents 
excluded fr om prima ry 
outcome analysis (N=0)
 ﬂow 
P
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d
d
t
o
dFig. 2. Participant
arents in the decision aid arm had statistically signiﬁcantly
igher decisional conﬂict than parents in the control arm (p = 0.01).
owever, parents in all three arms reported levels of decisional
onﬂict associated with difﬁculties in making an informed deci-
ion (Table 2). Post-intervention, mean decisional conﬂict had
ecreased for parents in both intervention arms to below 2, a
evel associated with informed decision-making. Trial arm was
igniﬁcantly associated (p < 0.001) with decisional conﬂict post-
ntervention. The greatest reduction in decisional conﬂict occurred
or parents in the decision aid arm, and this was evident for all ﬁve
ubscales (all p < 0.001; Table 2). There was no reduction in deci-
ional conﬂict (or any of the subscales) over time in the control arm
all p > 0.1; Table 2).
Three outcome measures at baseline were associated with
ecisional conﬂict post-intervention (Table 3). Speciﬁcally, higher
ecisional conﬂict, higher anxiety and less positive immunisation
rade-off beliefs (i.e. less sure that the necessity of the vaccine
utweighs the concerns) at baseline were associated with higher
ecisional conﬂict post-intervention.through the trial.
3.3. Impact of the decision aid and leaﬂet interventions on MMR
uptake
MMR  vaccination uptake data for 203 children (93%) were col-
lected from GP practices. Of these parents 48 were in the decision
aid arm, 85 in the leaﬂet arm and 70 in the control arm. Vaccination
uptake was 100%, 91% and 99%, respectively (2 (1, N = 203) = 8.69;
p (using Fishers exact test) = 0.017). Post-hoc tests revealed a sta-
tistically signiﬁcant difference in uptake between the leaﬂet and
control arms (8%, 95% CI 1–15%, p = 0.04), and between the decision
aid and leaﬂet arms (9%, 95% CI 3–16%, p = 0.05), but not between
the decision aid and control arms (1%, 95% CI −1 to 4%, p = 0.99).
3.4. Parents’ engagement with the decision aid and leaﬂet
interventionsThirty nine of the 50 parents in the decision aid arm responded
to the question about their use of the decision aid, 87% reported
working through the entire website. The mean length of time taken
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Table 2
Descriptive data for decisional conﬂict scale and subscales.
Decision aid Leaﬂet Control p-value
Mean 95% CI n Mean 95% CI n Mean 95% CI n
Decisional conﬂicta Baseline 2.82 2.57–3.07 44 2.59 2.40–2.77 83 2.41 2.21–2.60 68 <0.001b
Post-intervention 1.57c 1.37–1.78 43 1.89c 1.75–2.02 80 2.49 2.29–2.70 67
Uncertaintya Baseline 2.97 2.67–3.27 47 2.63 2.38–2.88 86 2.47 2.19–2.75 70 <0.001b
Post-intervention 1.65c 1.44–1.87 44 2.07c 1.87–2.27 81 2.53 2.25–2.81 68
Informeda Baseline 3.06 2.78–3.34 48 2.98 2.76–3.21 86 2.83 2.59–3.06 72 <0.001b
Post-intervention 1.45c 1.27–1.63 44 1.91c 1.73–2.09 82 2.85 2.60–3.09 69
Values claritya Baseline 2.86 2.58–3.13 46 2.71 2.48–2.94 86 2.51 2.25–2.78 72 <0.001b
Post-intervention 1.45c 1.29–1.60 44 1.79c 1.64–1.94 82 2.50 2.27–2.73 69
Supporta Baseline 2.55 2.33–2.77 47 2.38 2.20–2.55 86 2.34 2.14–2.53 70 <0.001b
Post-intervention 1.53c 1.32–1.73 43 1.92c 1.76–2.07 82 2.52 2.31–2.72 69
Effective decisiona Baseline 2.44 2.23–2.65 47 2.23 2.06–2.39 87 2.10 1.91–2.29 71 <0.001b
Post-intervention 1.44c 1.30–1.59 44 1.81c 1.67–1.95 81 2.22 2.03–2.40 68
a Decisional conﬂict and subscales: values range from 1 (no decisional conﬂict) to 5 (high decisional conﬂict). A decisional conﬂict score lower than two is associated with
implementing an informed decision [23]. A score lower than two  on the subscales represents levels of uncertainty, being informed, values clarity, support and effective
decision-making associated with informed decision-making [23].
b Statistically signiﬁcant value for time by arm interaction identiﬁed in repeated measures ANOVA.
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pStatistically signiﬁcant within-arm difference (p < 0.001) from baseline to post-
as 11.04 min. Parents spent most time on ‘Frequently Asked Ques-
ions’ (M = 4.56 min). Eighty of the 93 parents in the leaﬂet arm
esponded to the question about their use of the leaﬂet, 98% read
he whole leaﬂet.
The mean time parents spent looking at ‘other MMR  infor-
ation’ was 91.66 min  (95% CI = 71.51–111.80, n = 128). One-way
NOVA revealed no statistically signiﬁcant difference between the
hree arms (F (2,125) = 0.15, p = 0.86).
. Discussion
This is the ﬁrst cluster randomised controlled trial evaluating the
ffectiveness of a decision aid versus a leaﬂet versus usual practice
or a childhood immunisation decision. Impact was explored on two
utcomes relevant to childhood immunisation, informed decision-
aking and MMR  uptake [32–34]. Only the decision aid achieved
oth outcomes. Several study limitations are acknowledged. Nine-
een per cent of GP practices agreed to take part however only 16%
rovided parents (21% of all parents invited). Possible deterrents
o practice enrolment were concerns about associated workload,
mbivalence towards decision aids and fears of a negative impact
n vaccination uptake. As a consequence we did not meet our
nitial recruitment target. However, we consider the study was  suf-
ciently powered to draw meaningful conclusions because the ICC
nd the number of parents per cluster were lower than estimates
sed in the sample size calculation, meaning that the sample size
nﬂation factor, and therefore the required sample size, had been
ver-estimated [29]. We  do not know if parents who took part
able 3
oefﬁcients for the ANCOVA modelling of post-intervention decisional conﬂict on
otential covariates.
Variable Effect estimatea (95%
conﬁdence interval)
p-Value
Control (n = 93) – <0.001
Leaﬂet (n = 77) –0.67 (–0.88 to –0.46)
Decision aid (n = 50) –1.09 (–1.36 to –0.82)
Decisional conﬂict at baseline 0.37 (0.24–0.49) <0.001
Anxiety at baseline 0.010 (0.001–0.019) 0.041
MMR  immunisation trade-off beliefs –0.030 (–0.054 to –0.005) 0.019
a Results are presented per one point increase of decisional conﬂict.ention identiﬁed in post hoc tests.
were different to non-responders, although their characteristics
were consistent with parents who ﬁnd making the MMR  deci-
sion difﬁcult [30,31]. We  are conﬁdent that the sample is broadly
representative of the target audience for this decision aid, that
is ‘hesitant’ and ‘late or selective’ vaccinators [8,30] representing
20–30% and 2–27% of parents, respectively [33,35–38]. Due to the
study timeframe we  recorded MMR  uptake at 15 months of age
instead of 24 months which is used for national COVER (Cover of
Vaccination Evaluated Rapidly; [39]) data. Uptake may  have been
higher (in the leaﬂet and control arms) by 24 months. Finally, com-
plete case analysis for the primary outcome was  undertaken on just
55% of the data. Although we  found no evidence of selection bias
this remains a possibility.
Our ﬁnding that parents receiving the decision aid had lower
decisional conﬂict than those receiving usual practice is consistent
with evaluations of decision aids in other contexts [40]. The positive
effect of the leaﬂet mirrors our previous research [19]. The positive
impact of the decision aid on both vaccination uptake (which was
higher than uptake across the ﬁve participating PCTs at the time of
the study [21]) and decisional conﬂict is in keeping with previous
quasi-experimental evaluations of childhood immunisation deci-
sion aids [15–17]. What are the possible explanations for ﬁrst, the
differences between vaccination uptake in the leaﬂet and decision
aid arms (in which parents had levels of decisional conﬂict asso-
ciated with informed decision-making); and second for the high
uptake in the control arm when parents experienced high levels of
decisional conﬂict?
First, the decision aid framed MMR  vaccination as a choice
between two  options, to have or to not have the vaccination, rather
than as an opportunity to have a vaccination as presented in the
leaﬂet. Importantly, it included an interactive values clariﬁcation
exercise [41,42] which prompted parents to deliberate about their
child having the vaccine or catching the diseases. It is plausible that
this deliberation process may  have enabled parents to use the infor-
mation effectively [13,14] to make a decision consistent with their
values [43], thus prompting action. Reading the information leaﬂet
appears to have been sufﬁcient for parents to feel that they had
made an informed decision but they may have based their decision
on the issues they focused on at that time, which are often emo-
tions such as anticipated regret [13,14], rather than the evidence.
This is consistent with the ﬁndings of our previous study [19] and
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ther childhood immunisation research [13,14,43]. It seems likely
hat the lower rate of uptake in the leaﬂet arm reﬂected parental
nertia rather than vaccination rejection.
Second, uptake in the control group (99%) was very similar to
ptake in the decision aid arm (100%). One could then question
hether interventions to support decision-making are worthwhile
s an uptake rate of ≥95% is a successful population health out-
ome [9]. However, the two arms differed signiﬁcantly in the extent
o which decision-making was informed. Post-intervention, deci-
ional conﬂict was reduced to a level associated with informed
ecision-making in parents receiving the decision aid while in
he control arm was unchanged from baseline. So while parents
xposed to the decision aid were making a deliberative informed
ecision to have their child vaccinated, parents in the control arm
ay  have been adopting a position of ‘unquestioning acceptor’
33]. Our earlier research [44] found that whilst most parents took
heir children to be vaccinated, two thirds reported that they had
ot made an informed decision, with some experiencing decision
egret.
Finally, it may  be argued that our ﬁndings can be attributed to
he mode of information delivery (internet versus paper). How-
ver, increasing evidence indicates that it is the components of the
ecision aid (rather than the mode of delivery) that enable more
nformed decisions to be acted upon [45].
. Conclusions
The concern about using decision aids in the context of immun-
sation is that their focus on individual choice and autonomy
otentially conﬂicts with public health goals by deterring uptake
f programmes with evidence of effectiveness [46–48]. The con-
equences of which are particularly important when a parent’s
ecision to not vaccinate their child has implications for the wider
ommunity [46]. Our ﬁndings, building on those of others [15,16],
uggest this concern is unfounded. Moreover, simply providing
nformation without supporting parents to use it effectively may
eter timely uptake of the ﬁrst MMR  dose, although this warrants
urther investigation. The challenge then is two-fold; to encourage
ealth professionals and public health organisations to value deci-
ion support for immunisation decisions [49]; and to identify ways
f implementing tools like decision aids into routine practice that
re not burdensome to parents or health professionals [34,49,50].
he ﬁrst should be achievable as health professionals and public
ealth organisations are central in addressing parental concerns
bout vaccine safety [33,44]; and these tools appear to help meet
ptake targets attached to ﬁnancial incentives [34,51]. Regarding
mplementation, the web  address for a decision aid could be incor-
orated into invitation letters sent to parents to use in advance
f the appointment so they can come to the appointment ready
o discuss MMR  if they so choose. For parents who may  be less
ikely to access this type of support, perhaps due to health literacy
arriers [52] or cultural norms that don’t value patient autonomy
53], other approaches to decision support need to be explored.
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